Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic M3 receptor

Details for Australian Patent Application No. 2004251867 (hide)

Owner Novartis AG

Inventors Collingwood, Stephen Paul; Mccarthy, Clive; Baettig, Urs

Agent Davies Collison Cave

Pub. Number AU-B-2004251867

PCT Pub. Number WO2005/000815

Priority 0327526.0 26.11.03 GB; 0314697.4 24.06.03 GB

Filing date 23 June 2004

Wipo publication date 6 January 2005

Acceptance publication date 7 August 2008

International Classifications

C07D 211/46 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

C07D 207/08 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 211/22 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D 409/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

Event Publications

12 January 2006 PCT application entered the National Phase

  PCT publication WO2005/000815 Priority application(s): WO2005/000815

7 August 2008 Application Accepted

  Published as AU-B-2004251867

4 December 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004251868-Substituted diketopiperazines and their use as oxytocin antagonists

2004251866-Pharmaceutical composition comprising cyclic somatostatin analogues